NCT01973309View on ClinicalTrials.gov

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Vantictumab combined with paclitaxel

Vantictumab combined with paclitaxel will be administered IV.

Trial Locations (4)

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology-Tyler, Tyler

80045

University of Colorado Cancer Center, Aurora

90048

Cedars-Sinai Medical Center/ Samuel Oschin Comprehensive Cancer Institute, Los Angeles

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT01973309 - A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter